Knut Liepe
Department of Nuclear Medicine, Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany.
World J Nucl Med. 2015 Jan-Apr;14(1):10-5. doi: 10.4103/1450-1147.150509.
Radiosynovectomy is a well-established therapy in arthritis and involves an intra-articular injection of small radioactive particles to treat a synovitis. In Europe, frequent indications are rheumatoid and poly-arthritis. Especially in Germany radiosynovectomy is the second common therapy in Nuclear Medicine with about 40,000-60,000 treated joints per year. In Spain, USA, Turkey, Argentines and Philippines the therapy is more use in hemophilic arthritis with excellent results. Especially in developing countries with low availability of clotting factors, the radiosynovectomy represent a cost effective therapeutic option for repeated bleedings in hemophilic arthropathy. The special focus in these countries is maintaining of mobility and work ability. Often only the knee and medium joints (ankle, elbow and shoulder) are treated using yttrium-90, rhenium-186 or phosphorus-32. However, in rheumatoid arthritis most common affected joints are the fingers. For the treatment in these small joints, erbium-169 is necessary. Unfortunately, erbium-169 is only available in Europe. Further indications for radiosynovectomy are osteoarthritis and the articular effusion after joint replacement. The reported response rates in rheumatoid and poly-arthritis range from 60% to 80% depends from the stage of previous arthrosis. The best effectiveness of therapy was observed in hemophilic arthritis with response rate of 90% and significant reducing of bleeding frequency. The therapy is well-tolerated with low rate of side effects. In respect of the specific uptake of particles in the synovia and short range of beta radiation, the radiation exposure outside the joint is very low. The radiosynovectomy has efforts in comparison to surgical synovectomy: it's a minor intervention with low costs; and simultaneous treatments of multiple joints or treatment in short intervals are possible. The presented paper summarized the published papers and reports our own experiences in >15,000 treated joints.
放射性滑膜切除术是关节炎治疗中一种成熟的疗法,包括关节腔内注射小剂量放射性粒子以治疗滑膜炎。在欧洲,常见适应症为类风湿性关节炎和多关节炎。特别是在德国,放射性滑膜切除术是核医学中第二常见的疗法,每年约有40000 - 600关节接受治疗。在西班牙、美国、土耳其、阿根廷和菲律宾,该疗法在血友病性关节炎治疗中应用更为广泛,效果良好。特别是在凝血因子供应不足的发展中国家,放射性滑膜切除术是治疗血友病性关节病反复出血的一种经济有效的治疗选择。这些国家的特别关注点是维持关节活动度和工作能力。通常仅使用钇 - 90、铼 - 186或磷 - 32治疗膝关节和中等关节(踝关节、肘关节和肩关节)。然而,在类风湿性关节炎中,最常受累的关节是手指。对于这些小关节的治疗,需要使用铒 - 169。不幸的是,铒 - 169仅在欧洲有供应。放射性滑膜切除术的其他适应症包括骨关节炎和关节置换后的关节积液。据报道,类风湿性关节炎和多关节炎的有效率在60%至80%之间,这取决于既往关节炎的阶段。在血友病性关节炎中观察到该疗法的最佳疗效,有效率为90%,出血频率显著降低。该疗法耐受性良好,副作用发生率低。鉴于粒子在滑膜中的特异性摄取以及β射线的短射程,关节外的辐射暴露非常低。与手术滑膜切除术相比,放射性滑膜切除术有诸多优势:它是一种微创干预,成本低;并且可以同时治疗多个关节或在短时间间隔内进行治疗。本文总结了已发表的论文,并报告了我们在超过15000例治疗关节中的经验。